For research use only. Not for therapeutic Use.
OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5[1][2].
OICR-0547 does not bind to WDR5[1].
OICR-0547(0.1-100 μM) has no effect on cellular viability[1].
OICR-0547 (i.v, i.p.; 3, 30 mg/kg) is a suitable negative control in NOD-SCID Mice[2].
| Catalog Number | I012934 |
| CAS Number | 1801873-49-3 |
| Synonyms | N-[2-morpholin-4-yl-5-[3-(morpholin-4-ylmethyl)phenyl]phenyl]-6-oxo-4-(trifluoromethyl)-1H-pyridine-3-carboxamide |
| Molecular Formula | C28H29F3N4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C28H29F3N4O4/c29-28(30,31)23-16-26(36)32-17-22(23)27(37)33-24-15-21(4-5-25(24)35-8-12-39-13-9-35)20-3-1-2-19(14-20)18-34-6-10-38-11-7-34/h1-5,14-17H,6-13,18H2,(H,32,36)(H,33,37) |
| InChIKey | RFHOOFYUTGZPFH-UHFFFAOYSA-N |
| SMILES | C1COCCN1CC2=CC(=CC=C2)C3=CC(=C(C=C3)N4CCOCC4)NC(=O)C5=CNC(=O)C=C5C(F)(F)F |
| Reference | [1]. Grebien F, et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nat Chem Biol. 2015 Aug;11(8):571-578. [2]. Matthäus Getlik, et al. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1). J Med Chem. 2016 Mar 24;59(6):2478-96. |
